#USA #San Diego #Clinical Research #Aethlon Hemopurifier #Oncology Trial

Aethlon Medical's Progress in Oncology Clinical Trials

Aethlon Medical, Inc. (Nasdaq: AEMD), a pioneering biotechnology firm stationed in San Diego, is making notable strides in the clinical research arena with its investigational device, the Aethlon Hemopurifier®. This extracorporeal treatment is specifically designed for oncology applications and has recently received a positive review from an independent Data Safety Monitoring Board (DSMB), allowing the trial to progress into its third and final cohort.

The clinical trial, designated as AEMD-2022-06, aims to assess the safety and efficacy of the Hemopurifier among patients battling solid tumors who are currently under treatment involving Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®). Upon reviewing data from the second cohort of participants, the DSMB expressed that no significant safety concerns had surfaced, which is a promising endorsement for the Hemopurifier's use in clinical settings.

Details of the Latest Cohort

In the second cohort, participants received two treatments of the Hemopurifier over a one-week duration. With the DSMB's reaffirmation of its safety profile, Aethlon is geared to begin enrolling participants for the third cohort, where patients will undergo three treatments across one week. This phase is crucial, as it will continue to evaluate both safety and optimal dosing while further analyzing the device's effectiveness in reducing extracellular vesicle (EV) concentrations, which are implicated in tumor growth and immune response evasion.

Steven LaRosa, M.D., the Chief Medical Officer at Aethlon Medical, highlighted the significance of the DSMB's findings, stating, "The continued positive recommendations from the DSMB back the safety profile recorded thus far, propelling us into the final stages of our study."

The Hemopurifier's Mechanism of Action

The Aethlon Hemopurifier works by selectively removing enveloped viruses and tumor-derived extracellular vesicles from the bloodstream. Operating outside the body through a sophisticated blood pump, the device utilizes specialized plant lectin resin to target and eliminate EVs that are known to contribute to the spread of cancer and resist conventional therapies. Its capability to effectively diminish these harmful agents is supported by both in vitro and preliminary human studies, laying a strong foundation for its intended applications.

Currently, the Hemopurifier has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA) for treating patients with advanced cancer unresponsive to standard therapies and for combating life-threatening viruses. This designation underscores the device's potential transformative impact on clinical practices in oncology and infectious disease management.

Forward Plans and Future Studies

Looking ahead, Aethlon Medical remains committed to progressing the Hemopurifier through clinical testing. The results from this and future cohorts will not only shed light on its immediate impacts but are also expected to shape the framework for subsequent efficacy trials necessary for regulatory approvals. The third cohort aims to enroll between 9 to 18 patients, targeting individuals with stable or progressing tumor conditions, revealing further insights into Hemopurifier's effectiveness.

In essence, the recent developments in Aethlon Medical’s clinical trial emphasize a crucial moment in the fight against cancer and other diseases, indicating a clear path toward innovative treatment options. The company’s proactive stance and unique approach could very well change how oncological treatments are administered and perceived in the near future, as updates continue to unfold in this ongoing trial.